That is very broad. You are talking about several things. You are talking about case studies. The report for all of Dr. McDiarmid's studies did not include case studies. It is the same for the Institute of Medicine studies.
Furthermore, the case studies are interesting when it comes to raising rare problems that have come up from the beginning. For example, these kinds of situations can arise in the case of new drugs, even though studies were done before patents were obtained. Even though studies have been conducted, some side effects can appear later, once the drugs have been used by a larger population over several years.
These case studies, for example someone who has rare side effects, will be published. Let me be clear that these case studies will be published, because that may give rise to a certain dialogue. We find out about one case study, which sparks another in another country, and so on. However, these studies are not included in epidemiological studies on large populations.
As for the Valcartier studies, I know nothing about them. I am not aware of that. We would have heard about it if there were studies at Valcartier having to do with depleted uranium, which I highly doubt. The only study by the Royal Military College had to do with urine tests.